Alrex (loteprednol etabonate) NDC 24208-353

NDC codes

FDA NDC Directory

Product NDC (as listed)24208-353Labeler and product segments. Claims need a package NDC.

Product NDC at billing width24208-0353Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
24208-353-01	24208035301	1 BOTTLE, DROPPER in 1 CARTON (24208-353-01) / 1 mL in 1 BOTTLE, DROPPERMarketed from Mar 9, 1998 · Sample package
24208-353-05	24208035305	1 BOTTLE, DROPPER in 1 CARTON (24208-353-05) / 5 mL in 1 BOTTLE, DROPPERMarketed from Mar 9, 1998
24208-353-10	24208035310	1 BOTTLE, DROPPER in 1 CARTON (24208-353-10) / 10 mL in 1 BOTTLE, DROPPERMarketed from Mar 9, 1998

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Alrex
Generic name (nonproprietary): loteprednol etabonate
Active ingredients: Loteprednol etabonate — 2 mg/mL
Dosage form: Suspension/ drops
Route: Ophthalmic
Labeler: Bausch & Lomb Incorporated
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 020803
Marketing start: Mar 9, 1998
Listing expires: Dec 31, 2026
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 24208-353_138577af-1a4e-48fb-b088-47f54c896442SPL ID 138577af-1a4e-48fb-b088-47f54c896442SPL set ID 21c76da0-50a1-41c0-91b8-8cc4dcc27f60RxCUI 213262, 311381UNII YEH1EZ96K6UPC 0324208353103
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Ophthalmic products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N424208035301 followed by a unit qualifier and the quantity

Package 24208-0353-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 31, 2022.

Indications (excerpt from the label)

INDICATIONS AND USAGE ALREX ophthalmic suspension is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 020803

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 020803
Product	Strength	Form · route	Labeler	Product NDC
loteprednol etabonate	Loteprednol etabonate 2 mg/mL	Suspension/ dropsOphthalmic	Bausch & Lomb Americas Inc.	82260-361